INVEGA TRINZA 546 MG/1.75 ML
FDA nonproprietary name: paliperidone palmitate
For 1 mL
Pharmacies pay
$3,993.63 filed
1 × $3,993.63408 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$3,985.21 filed
1 × $3,985.20601 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.0× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Invega Trinza” / “Paliperidone Palmitate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$4,597.67 estimated
$3,993.63 + $599.04 (15%) + $5.00 fee per fill = $4,597.67
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
INVEGA TRINZA 546 MG/1.75 ML is how the CMS NADAC file names this product. The FDA NDC Directory lists it as paliperidone palmitate, under the trade name “INVEGA TRINZA”.
FDA gives its dosage form as injection, suspension, extended release and its route as intramuscular.
The labeler, the company named on the label, is Janssen Pharmaceuticals, Inc.
FDA’s Established Pharmacologic Class for it is Atypical Antipsychotic.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50458-0608-01.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $3,993.63 for 1 mL (1 × $3,993.63408 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
The NDC
- 50458-0608-01 · Janssen Pharmaceuticals, Inc · $3,993.63408 per ML · eff. 2026-09-23 filed
Other strengths, forms and brands
10 other products in the NADAC file share the FDA nonproprietary name paliperidone palmitate with INVEGA TRINZA 546 MG/1.75 ML.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| INVEGA HAFYERA 1,092 MG/3.5 ML | $4,047.70905 per ML filed | $4,143.61081 per ML filed |
| INVEGA HAFYERA 1,560 MG/5 ML | $4,233.40151 per ML filed | $4,143.61081 per ML filed |
| INVEGA SUSTENNA 39 MG/0.25 ML | $2,338.748 per ML filed | $2,352.6638 per ML filed |
| INVEGA SUSTENNA 78 MG/0.5 ML | $2,337.04833 per ML filed | $2,352.6638 per ML filed |
| INVEGA SUSTENNA 117 MG/0.75 ML | $2,339.66855 per ML filed | $2,352.6638 per ML filed |
| INVEGA SUSTENNA 156 MG/ML SYRG | $2,337.70833 per ML filed | $2,352.6638 per ML filed |
| INVEGA SUSTENNA 234 MG/1.5 ML | $2,338.47458 per ML filed | $2,352.6638 per ML filed |
| INVEGA TRINZA 273 MG/0.88 ML | $3,950.94887 per ML filed | $3,985.20601 per ML filed |
| INVEGA TRINZA 410 MG/1.32 ML | $3,959.46212 per ML filed | $3,985.20601 per ML filed |
| INVEGA TRINZA 546 MG/1.75 ML this page | $3,993.63408 per ML filed | $3,985.20601 per ML filed |
| INVEGA TRINZA 819 MG/2.63 ML | $3,997.97064 per ML filed | $3,985.20601 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
Its NADAC price is $3,993.63408 per ML filed.
Of the 25 other products in FDA’s Atypical Antipsychotic class priced per ML, 8 have a higher middle NADAC price and 17 a lower one. The one in the middle is INVEGA SUSTENNA 234 MG/1.5 ML, at $2,338.47458 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $3,985.21 for 1 mL, at an average of $3,985.20601 per ML in 2024 (2024-01-01 to 2024-12-31) for “Invega Trinza” and “Paliperidone Palmitate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 63,911 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for INVEGA TRINZA 546 MG/1.75 ML labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Invega Trinza / Paliperidone Palmitate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 1 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1 mL in one package for this product’s NDC (“1 SYRINGE in 1 KIT (50458-608-01) / 1 mL in 1 SYRINGE”), so the card starts at one package: 1 ML. Change it to match your prescription.
Related pages
Its pharmacologic class
Related in the same class
- QUETIAPINE 150 MG TABLET
- OLANZAPINE 10 MG TABLET
- CLOZAPINE 100 MG TABLET
- LURASIDONE HCL 120 MG TABLET
- VRAYLAR 0.5 MG CAPSULE